# Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants

> **NCT05330858** · PHASE1 · COMPLETED · sponsor: **Alumis Inc** · enrollment: 14 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** ESK-001
- **DRUG:** Rabeprazole

## Key facts

- **NCT ID:** NCT05330858
- **Lead sponsor:** Alumis Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-17
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-09-20
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330858, "Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05330858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*